New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis
about
Does Cannabidiol Protect Against Adverse Psychological Effects of THC?Neurodegeneration in multiple sclerosis: novel treatment strategiesThe endocannabinoid system as an emerging target of pharmacotherapyBrain innate immunity in the regulation of neuroinflammation: therapeutic strategies by modulating CD200-CD200R interaction involve the cannabinoid systemThe non-psychoactive plant cannabinoid, cannabidiol affects cholesterol metabolism-related genes in microglial cells.Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors.Endocannabinoids and immune regulation.The endocannabinoid system and painTargeting the endocannabinoid system in treating brain disorders.The cannabinoid system and its pharmacological manipulation--a review, with emphasis upon the uptake and hydrolysis of anandamide.The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitisModulation of breast cancer cell viability by a cannabinoid receptor 2 agonist, JWH-015, is calcium dependent.Targeting the endocannabinoid system: to enhance or reduce?Preclinical models of muscle spasticity: valuable tools in the development of novel treatment for neurological diseases and conditions.Anandamide enhances IL-10 production in activated microglia by targeting CB(2) receptors: roles of ERK1/2, JNK, and NF-kappaB.A drug discovery case history of 'delta-9-tetrahydrocannabinol, cannabidiol'.CD200-CD200R1 interaction contributes to neuroprotective effects of anandamide on experimentally induced inflammation.The Endocannabinoid Reuptake Inhibitor WOBE437 Is Orally Bioavailable and Exerts Indirect Polypharmacological Effects via Different Endocannabinoid Receptors.Traditional Uses of Cannabinoids and New Perspectives in the Treatment of Multiple Sclerosis
P2860
Q21129107-8780D9B0-4DFF-4CFF-B458-085BA38B8C6BQ22241472-83AE1DFF-7FF7-4000-BDC9-345466E6A734Q24648473-03B1C62C-9187-4CFA-9CB1-2F2289B4B92FQ26865295-154684FB-00EC-4AD2-9351-2B9231F98F02Q34181605-B853E8AF-3A9D-453D-9576-6AD5D834DF70Q34574015-E54906C4-EA92-4CC7-BFB4-5B2671E884B1Q34607419-5E901E43-A1D7-4229-9917-04EBA3E35B67Q34612917-05DAB977-B2A6-4D46-8552-C8557887DC02Q36425999-34FF7E9D-A20F-411E-9120-9C1D53F94BB4Q36655240-B25D08D3-EAD6-4E7B-806F-082A715D0E05Q36784020-4A7C7AB6-F731-4B88-8296-279DE0884412Q36843205-D771CB01-E219-4701-8919-C720909EBAC8Q37150745-419C6C0A-7C47-444C-A0A1-F37D6A90644FQ38727855-381BF7EF-5949-4CAE-B277-AC889D9AB36DQ39831195-467D32A7-3687-4458-865D-5D1E762F374BQ44830885-06B9020B-061B-4F60-AFA9-734C51C11390Q48486771-B6782D6D-DE13-4A56-A885-ED64EFC97C8EQ55077096-312F9352-D318-4AA1-A5D1-8CF60F3B6B4DQ58775742-BCCCD41D-36D8-4266-8F55-70831EAC7F76
P2860
New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
New potent and selective inhib ...... se model of multiple sclerosis
@ast
New potent and selective inhib ...... se model of multiple sclerosis
@en
type
label
New potent and selective inhib ...... se model of multiple sclerosis
@ast
New potent and selective inhib ...... se model of multiple sclerosis
@en
prefLabel
New potent and selective inhib ...... se model of multiple sclerosis
@ast
New potent and selective inhib ...... se model of multiple sclerosis
@en
P2093
P2860
P50
P921
P356
P1476
New potent and selective inhib ...... se model of multiple sclerosis
@en
P2093
Alessia Ligresti
Anu Mahadevan
Bijali Saha
Cristina Visintin
David Baker
Gareth Pryce
Irina Beletskaya
Luciano De Petrocellis
Maria Grazia Cascio
Raj K Razdan
P2860
P356
10.1038/SJ.BJP.0706418
P407
P577
2006-01-01T00:00:00Z